Mary Madison, RN, RAC-CT, CDP
Clinical Consultant – Briggs Healthcare
The U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorizations (EUA) for monoclonal antibodies to treat COVID-19 for certain patients. Monoclonal antibodies may be available through expanded access programs to treat COVID-19 for immunocompromised patients. However, the efficacy of use for immunocompromised patients is unclear.
During this COCA Call, presenters will discuss the FDA’s role in issuing EUAs for certain monoclonal antibodies, options for compassionate use, the process for ordering and distributing monoclonal antibodies, and current data on using monoclonal antibodies for both non-hospitalized and immunocompromised patients. Presenters will also cover preventing, diagnosing, and treating COVID-19 in immunocompromised patients, including the role of monoclonal antibodies, serologic testing, and potential third dose of COVID-19 vaccinations.
Date: Thursday, August 12, 2021
Time: 2:00 PM – 3:00 PM ET
A few minutes before the webinar starts, please click on the Zoom link below to join:
US: +1 669 254 5252
or +1 646 828 7666
or +1 669 216 1590
or +1 551 285 1373
Or One-tap mobile:
Webinar ID: 161 225 4638
International numbers available: https://www.zoomgov.com/u/awoXk0deU
If you are unable to attend the live COCA Call, the recording will be available for viewing on the COCA Call webpage a few hours after the live event ends.
The slide set will be available on the day of the call under “Call Materials” on the COCA Call webpage.
Free Continuing Education (CE) will be offered for this COCA Call.
Registration is not required.